Alzheimer's disease
In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …
Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab
M Shi, F Chu, F Zhu, J Zhu - Frontiers in aging neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of …
E McDade, JL Cummings, S Dhadda… - Alzheimer's research & …, 2022 - Springer
Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …
[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …
affecting around 46 million people worldwide but few treatments are currently available. The …
Amyloid beta in aging and Alzheimer's disease
Alzheimer's disease (AD), is a progressive neurodegenerative disease that affects behavior,
thinking, learning, and memory in elderly individuals. AD occurs in two forms, early onset …
thinking, learning, and memory in elderly individuals. AD occurs in two forms, early onset …
Immunotherapy for Alzheimer's disease: Targeting β-amyloid and beyond
C Song, J Shi, P Zhang, Y Zhang, J Xu, L Zhao… - Translational …, 2022 - Springer
Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly
worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the …
worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the …
The dawn of a new era: targeting the “undruggables” with antibody-based therapeutics
The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease
Background: The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …
Alzheimer's disease
JAS Lopez, HM González, GC Léger - Handbook of clinical neurology, 2019 - Elsevier
Alzheimer's disease (AD) dementia refers to a particular onset and course of cognitive and
functional decline associated with age together with a particular neuropathology. It was first …
functional decline associated with age together with a particular neuropathology. It was first …
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in
the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show …
the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show …